Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea

Choi, Kui Son; Jun, Jae Kwan; Suh, Mi Na; Park, B.; Noh, Dai Keun; Song, Seung Hoon; Jung, Kyu Won; Lee, H. Y.; Choi, Il Ju; Park, E. C.

doi:10.1038/bjc.2014.608

Cited by 130 publications

(90 citation statements)

References 15 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These measures can be broadly classified into two groups: those that aim to detect gastric cancer itself (cancer screening), and those that aim to evaluate the premalignant condition of gastric mucosa (risk stratification) [2]. Double-contrast upper gastrointestinal barium X-ray radiography (UGI-XR) [3][4][5] and upper gastrointestinal endoscopy (UGI-ES) [6][7][8] are the typical measures belonging to the former group, whereas serum markers including anti-Helicobacter pylori (H. pylori) IgG, pepsinogens, gastrin-17, methylation status of several genes, etc. [9][10][11][12][13][14] are representative measures affiliated with the latter group.…”

Section: Introductionmentioning

confidence: 99%

Comparative analysis of upper gastrointestinal endoscopy, double-contrast upper gastrointestinal barium X-ray radiography, and the titer of serum anti-Helicobacter pylori IgG focusing on the diagnosis of atrophic gastritis

et al. 2015

View full text Add to dashboard Cite

Background Upper gastrointestinal endoscopy (UGI-ES) and double-contrast upper gastrointestinal barium X-ray radiography (UGI-XR) are two major image-based methods to diagnose atrophic gastritis, which is mostly induced by Helicobacter pylori infection. However, there have been few studies directly comparing them. Methods Atrophic gastritis was evaluated using the data of 962 healthy subjects who underwent UGI-ES and UGI-XR within 1 year. Results and conclusion Based on UGI-ES and UGI-XR, 602 subjects did not have atrophic gastritis and 254 subjects did have it. Considering UGI-ES-based atrophic gastritis as the standard, sensitivity and specificity of UGI-XR-based atrophic gastritis were 92.0 % (254/276) and 92.8 % (602/649), respectively. The seven-grade KimuraTakemoto classification of UGI-ES-based atrophic gastritis showed a strong and significant association with the fourgrade UGI-XR-based atrophic gastritis. Sensitivity and specificity of serum anti-Helicobacter pylori IgG to detect UGI-ES/UGI-XR-based atrophic gastritis were 89.4 % (227/254) and 99.8 % (601/602), indicating that atrophic gastritis can be overlooked according to serum anti-Helicobacter pylori IgG alone.Keywords Atrophic gastritis Á Helicobacter pylori Á Upper gastrointestinal endoscopy (UGI-ES) Á DoubleElectronic supplementary material The online version of this article

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative analysis of upper gastrointestinal endoscopy, double-contrast upper gastrointestinal barium X-ray radiography, and the titer of serum anti-Helicobacter pylori IgG focusing on the diagnosis of atrophic gastritis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Although studies have shown reductions in stomach cancer mortality in screened populations, the target group, onset, and modality of screening programs remain controversial. 37,[42][43][44][45][46] Prevention and treatment of carcinogenic infections that lead to these observed cancer patterns in low SDI countries have the potential to decrease future cancer burden as well as reducing associated diseases like cirrhosis in endemic areas. 47 In addition, limiting transmission can lead to prevention efforts that are sustained beyond 1 generation.…”

mentioning

confidence: 99%

Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: A systematic analysis for the Global Burden of Disease study.

Fitzmaurice

2018

JCO

1,869

2,114

View full text Add to dashboard Cite

Global Burden of Disease Cancer CollaborationIMPORTANCE Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. OBJECTIVE To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015.EVIDENCE REVIEW Cancer mortality was estimated using vital registration system data, cancer registry incidence data (transformed to mortality estimates using separately estimated mortality to incidence [MI] ratios), and verbal autopsy data. Cancer incidence was calculated by dividing mortality estimates through the modeled MI ratios. To calculate cancer prevalence, MI ratios were used to model survival. To calculate YLDs, prevalence estimates were multiplied by disability weights. The YLLs were estimated by multiplying age-specific cancer deaths by the reference life expectancy. DALYs were estimated as the sum of YLDs and YLLs. A sociodemographic index (SDI) was created for each location based on income per capita, educational attainment, and fertility. Countries were categorized by SDI quintiles to summarize results. FINDINGSIn 2015, there were 17.5 million cancer cases worldwide and 8.7 million deaths. Between 2005 and 2015, cancer cases increased by 33%, with population aging contributing 16%, population growth 13%, and changes in age-specific rates contributing 4%. For men, the most common cancer globally was prostate cancer (1.6 million cases). Tracheal, bronchus, and lung cancer was the leading cause of cancer deaths and DALYs in men (1.2 million deaths and 25.9 million DALYs). For women, the most common cancer was breast cancer (2.4 million cases). Breast cancer was also the leading cause of cancer deaths and DALYs for women (523 000 deaths and 15.1 million DALYs). Overall, cancer caused 208.3 million DALYs worldwide in 2015 for both sexes combined. Between 2005 and 2015, age-standardized incidence rates for all cancers combined increased in 174 of 195 countries or territories. Age-standardized death rates (ASDRs) for all cancers combined decreased within that timeframe in 140 of 195 countries or territories. Countries with an increase in the ASDR due to all cancers were largely located on the African continent. Of all cancers, deaths between 2005 and 2015 decreased significantly for Hodgkin lymphoma (−6.1% [95% uncertainty interval (UI), −10.6% to −1.3%]). The number of deaths also decreased for esophageal cancer, stomach cancer, and chronic myeloid leukemia, although these results were not statistically significant. CONCLUSION AND RELEVANCEAs part of the epidemiological transition, cancer incidence is expected to increase in the future, further straining limited health care resources. Appropriate allocation of resources for cancer prevention, early diagnosis, and curative and palliative care requires detailed knowledge of the local burden of cancer. The GBD 2015 study results demonstrate that progress ...

show abstract

“…In Korea, since a nationwide gastric cancer screening program was started in 1999 as part of the National Cancer Screening Program, persons 40 years or older have been undergoing biennial upper endoscopies or upper gastrointestinal series. 2 Owing to mass screening programs and recent improvements in diagnostic technique, early detection in a resectable state followed by treatment of gastric cancer has increased and, therefore, the overall survival rates have increased. 2 Until now, in patients ＜40 years, routine gastric cancer screening is not recommended.…”

Section: Introductionmentioning

confidence: 99%

“…2 Owing to mass screening programs and recent improvements in diagnostic technique, early detection in a resectable state followed by treatment of gastric cancer has increased and, therefore, the overall survival rates have increased. 2 Until now, in patients ＜40 years, routine gastric cancer screening is not recommended. Gastric cancer is predominantly diagnosed in older patients.…”

Section: Introductionmentioning

confidence: 99%

Clinical Outcomes of Endoscopic Submucosal Dissection in Patients under 40 Years Old with Early Gastric Cancer

Hahn

Lee

Park

et al. 2016

Korean J Helicobacter Up Gastrointest Res

View full text Add to dashboard Cite

Background/Aims: The clinicopathologic features of gastric cancer in young patients are different from those of older patients. However, endoscopic submucosal dissection (ESD) is performed regardless of age. The purpose of this study was to characterize younger patients (≤40 years) who underwent ESD for early gastric cancer (EGC) and analyze the results of ESD. Materials and Methods: From January 2006 to June 2014, 55 patients aged 40 years or younger with newly diagnosed EGC underwent ESD at two tertiary hospitals. The clinicopathologic features of EGC and clinical outcomes of ESD in these young patients were reviewed retrospectively. Results: A total 55 patients with 57 EGC lesions underwent ESD. Female sex, superficial flat or depressed lesions, and undifferentiated histology were more common in younger patients than in older patients in our institutional ESD cohort. The en bloc resection rate was 92.7% and the complete resection rate was 94.5%. Although there was a high proportion of undifferentiated cancer in the younger patient group, the curative resection rate was 72.7%. Among 15 patients with non-curative resection, 4 patients underwent additional surgery and 1 patient underwent argon plasma coagulation at the ESD ulcer margin. Eight patients were placed under close surveillance without additional treatment, and no recurrent tumors developed, with a median follow-up period of 37.2±23.6 months. Conclusions: Younger EGC patients who underwent ESD showed the typical characteristics seen in younger patients with gastric cancer. ESD in younger EGC patients showed comparable outcomes to those in patients with undifferentiated EGC in general.

show abstract

Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea

Cited by 130 publications

References 15 publications

Comparative analysis of upper gastrointestinal endoscopy, double-contrast upper gastrointestinal barium X-ray radiography, and the titer of serum anti-Helicobacter pylori IgG focusing on the diagnosis of atrophic gastritis

Comparative analysis of upper gastrointestinal endoscopy, double-contrast upper gastrointestinal barium X-ray radiography, and the titer of serum anti-Helicobacter pylori IgG focusing on the diagnosis of atrophic gastritis

Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: A systematic analysis for the Global Burden of Disease study.

Clinical Outcomes of Endoscopic Submucosal Dissection in Patients under 40 Years Old with Early Gastric Cancer

Contact Info

Product

Resources

About